Hadjinor, Darwisa .
HRN: 21-10-43 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/17/2023
CEFUROXIME 500MG (TAB)
10/17/2023
10/24/2023
PO
500 Mg Tab
BID
S/P REPEAT LSCS
Waiting Final Action
Indication: Empirical De-escalation Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes